Free Trial

Cambridge Cognition (COG) Competitors

Cambridge Cognition logo
GBX 28.40 +0.40 (+1.43%)
As of 03:19 AM Eastern

COG vs. RENX, INHC, FDBK, IQAI, and DVRG

Should you buy Cambridge Cognition stock or one of its competitors? Cambridge Cognition's main competitors and comparable companies include Renalytix (RENX), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), and DeepVerge (DVRG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Cambridge Cognition compare to Renalytix?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Renalytix has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, suggesting that its stock price is 19% less volatile than the broader market.

Cambridge Cognition has a net margin of -13.86% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-506.25% 675.00% -93.54%
Cambridge Cognition -13.86%-54.17%-0.30%

14.0% of Renalytix shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 6.0% of Renalytix shares are owned by company insiders. Comparatively, 3.3% of Cambridge Cognition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3.30M11.17-£109.93M-£4.00N/A
Cambridge Cognition£10.13M1.55-£1.58M-£3.10N/A

Cambridge Cognition has a consensus target price of GBX 56, indicating a potential upside of 93.10%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Renalytix and Renalytix both had 2 articles in the media. Cambridge Cognition's average media sentiment score of 0.34 beat Renalytix's score of -0.10 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Renalytix
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cambridge Cognition
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Cambridge Cognition beats Renalytix on 10 of the 15 factors compared between the two stocks.

How does Cambridge Cognition compare to Induction Healthcare Group?

Cambridge Cognition (LON:COG) and Induction Healthcare Group (LON:INHC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Cambridge Cognition presently has a consensus price target of GBX 56, indicating a potential upside of 93.10%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, research analysts clearly believe Cambridge Cognition is more favorable than Induction Healthcare Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Induction Healthcare Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.9% of Cambridge Cognition shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 3.3% of Cambridge Cognition shares are held by company insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cambridge Cognition has a beta of 0.809, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market.

In the previous week, Cambridge Cognition had 2 more articles in the media than Induction Healthcare Group. MarketBeat recorded 2 mentions for Cambridge Cognition and 0 mentions for Induction Healthcare Group. Cambridge Cognition's average media sentiment score of 0.34 beat Induction Healthcare Group's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the media.

Company Overall Sentiment
Cambridge Cognition Neutral
Induction Healthcare Group Neutral

Cambridge Cognition has a net margin of -13.86% compared to Induction Healthcare Group's net margin of -23.86%. Induction Healthcare Group's return on equity of -14.58% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Cognition-13.86% -54.17% -0.30%
Induction Healthcare Group -23.86%-14.58%-7.32%

Cambridge Cognition has higher earnings, but lower revenue than Induction Healthcare Group. Cambridge Cognition is trading at a lower price-to-earnings ratio than Induction Healthcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Cognition£10.13M1.55-£1.58M-£3.10N/A
Induction Healthcare Group£12.57M0.72-£5.12M-£5.54N/A

Summary

Cambridge Cognition beats Induction Healthcare Group on 11 of the 16 factors compared between the two stocks.

How does Cambridge Cognition compare to Feedback?

Cambridge Cognition (LON:COG) and Feedback (LON:FDBK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Cambridge Cognition had 2 more articles in the media than Feedback. MarketBeat recorded 2 mentions for Cambridge Cognition and 0 mentions for Feedback. Cambridge Cognition's average media sentiment score of 0.34 beat Feedback's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the media.

Company Overall Sentiment
Cambridge Cognition Neutral
Feedback Neutral

Cambridge Cognition has a beta of 0.809, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Cambridge Cognition presently has a consensus target price of GBX 56, indicating a potential upside of 93.10%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, equities analysts clearly believe Cambridge Cognition is more favorable than Feedback.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Feedback
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cambridge Cognition has a net margin of -13.86% compared to Feedback's net margin of -845.25%. Cambridge Cognition's return on equity of -54.17% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Cognition-13.86% -54.17% -0.30%
Feedback -845.25%-135.17%-22.99%

Cambridge Cognition has higher revenue and earnings than Feedback. Cambridge Cognition is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Cognition£10.13M1.55-£1.58M-£3.10N/A
Feedback£849.62K3.27-£10.84M-£15.74N/A

15.9% of Cambridge Cognition shares are held by institutional investors. Comparatively, 23.3% of Feedback shares are held by institutional investors. 3.3% of Cambridge Cognition shares are held by company insiders. Comparatively, 8.0% of Feedback shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cambridge Cognition beats Feedback on 12 of the 16 factors compared between the two stocks.

How does Cambridge Cognition compare to IQ-AI?

IQ-AI (LON:IQAI) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

IQ-AI has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, meaning that its stock price is 19% less volatile than the broader market.

In the previous week, Cambridge Cognition had 2 more articles in the media than IQ-AI. MarketBeat recorded 2 mentions for Cambridge Cognition and 0 mentions for IQ-AI. Cambridge Cognition's average media sentiment score of 0.34 beat IQ-AI's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company Overall Sentiment
IQ-AI Neutral
Cambridge Cognition Neutral

Cambridge Cognition has a net margin of -13.86% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -54.17% beat IQ-AI's return on equity.

Company Net Margins Return on Equity Return on Assets
IQ-AI-77.52% -140.75% -22.03%
Cambridge Cognition -13.86%-54.17%-0.30%

15.9% of Cambridge Cognition shares are owned by institutional investors. 66.0% of IQ-AI shares are owned by insiders. Comparatively, 3.3% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IQ-AI has higher earnings, but lower revenue than Cambridge Cognition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQ-AI£538.19K3.30N/AN/AN/A
Cambridge Cognition£10.13M1.55-£1.58M-£3.10N/A

Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 93.10%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Cambridge Cognition is more favorable than IQ-AI.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQ-AI
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cambridge Cognition beats IQ-AI on 11 of the 14 factors compared between the two stocks.

How does Cambridge Cognition compare to DeepVerge?

DeepVerge (LON:DVRG) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

4.2% of DeepVerge shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 9.5% of DeepVerge shares are held by company insiders. Comparatively, 3.3% of Cambridge Cognition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DeepVerge has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Cambridge Cognition had 2 more articles in the media than DeepVerge. MarketBeat recorded 2 mentions for Cambridge Cognition and 0 mentions for DeepVerge. Cambridge Cognition's average media sentiment score of 0.34 beat DeepVerge's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company Overall Sentiment
DeepVerge Neutral
Cambridge Cognition Neutral

Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 93.10%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than DeepVerge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DeepVerge
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cambridge Cognition has a net margin of -13.86% compared to DeepVerge's net margin of -19.81%. DeepVerge's return on equity of -10.27% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
DeepVerge-19.81% -10.27% -5.56%
Cambridge Cognition -13.86%-54.17%-0.30%

Cambridge Cognition has lower revenue, but higher earnings than DeepVerge. Cambridge Cognition is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DeepVerge£12.41M0.00-£2.46M-£0.01N/A
Cambridge Cognition£10.13M1.55-£1.58M-£3.10N/A

Summary

Cambridge Cognition beats DeepVerge on 10 of the 15 factors compared between the two stocks.

Get Cambridge Cognition News Delivered to You Automatically

Sign up to receive the latest news and ratings for COG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COG vs. The Competition

MetricCambridge CognitionHealthcare Technology IndustryHealthcare SectorLON Exchange
Market Cap£15.33M£1.79B£7.19B£2.79B
Dividend YieldN/A3.97%2.53%6.21%
P/E Ratio-9.1621.58274.66367.12
Price / Sales1.5195.13568.5888,558.38
Price / Cash4.3131.8976.8227.89
Price / Book3.916.2610.886.90
Net Income-£1.58M-£19.09M£3.50B£5.89B
7 Day Performance3.20%-1.67%-1.84%-0.36%
1 Month Performance2.90%-0.11%-6.36%-0.81%
1 Year Performance-17.92%-22.68%3.07%21.91%

Cambridge Cognition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COG
Cambridge Cognition
1.597 of 5 stars
GBX 28.40
+1.4%
GBX 56
+97.2%
-21.6%£15.33M£10.13MN/A74
RENX
Renalytix
N/AGBX 5.87
-4.6%
N/A-36.4%£37.14M£3.30MN/A102
INHC
Induction Healthcare Group
N/AGBX 9.75
flat
N/A+0.0%£9.00M£12.57MN/A74
FDBK
Feedback
N/AGBX 6.40
+0.8%
N/A-38.0%£2.80M£849.62KN/A24
IQAI
IQ-AI
N/AGBX 0.80
flat
N/A+0.0%£1.77M£538.19KN/A6

Related Companies and Tools


This page (LON:COG) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners